Detalhe da pesquisa
1.
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
Ann Oncol
; 34(8): 714-722, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37182801
2.
Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.
Ann Oncol
; 34(3): 262-274, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36535565
3.
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Ann Oncol
; 30(2): 297-302, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30481287
4.
Response-adapted volume de-escalation (RAVD) in locally advanced head and neck cancer.
Ann Oncol
; 27(5): 908-13, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26884588
5.
Comparison of outcomes of locoregionally advanced oropharyngeal and non-oropharyngeal squamous cell carcinoma over two decades.
Ann Oncol
; 26(1): 198-205, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25361984
6.
A randomized, phase II study of afatinib versus cetuximab in metastatic or recurrent squamous cell carcinoma of the head and neck.
Ann Oncol
; 25(9): 1813-1820, 2014 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24928832
7.
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.
Ann Oncol
; 30(10): 1673, 2019 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31168601
8.
A phase I dose escalation study of Ad GV.EGR.TNF.11D (TNFerade™ Biologic) with concurrent chemoradiotherapy in patients with recurrent head and neck cancer undergoing reirradiation.
Ann Oncol
; 24(3): 769-76, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23104721
9.
Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA.
Oral Oncol
; 49(6): 525-33, 2013 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-23490885
10.
State-of-the-art management of locally advanced head and neck cancer.
Br J Cancer
; 92(8): 1341-8, 2005 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-15846296